Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06104228 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Study acronym: Xenon PAH Bio
StatusRecruiting
PhasePhase 2
Started2024-08-12
View on ClinicalTrials.gov ↗

Amendment history

2026-02-23
Study Status, Oversight v9
Primary completion date2026-01-01→2027-01-01
Completion date2026-03-31→2027-03-31
2025-10-17
Study Status, Contacts/Locations v8
Re-verified, no change to tracked fields
2025-07-21
Study Identification, Study Status, Conditions, Contacts/Locations v7
Study sitescontacts updated at 1 of 1 site
Study titlerevised
129 Xenon MRI Asas a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
2024-09-09
Not Yet Recruiting→Recruiting Study Identification, Study Status, Oversight, Conditions, Contacts/Locations v6
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-09-01→confirmed 2024-08-12
Study sitesdetails revised at 1 of 1 site
Study titlerevised
129 Xenon MRI asAs a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
2024-07-16
Study Status v5
Start date2024-07-01→2024-09-01
Show 4 earlier versions
2024-05-17
Study Status v4
Start date2024-05-01→2024-07-01
2024-03-20
Study Status v3
Start date2024-03-01→2024-05-01
2024-01-16
Study Status v2
Start date2024-01-01→2024-03-01
2023-12-06
Study Status, IPDSharing v1
Re-verified, no change to tracked fields
2023-10-23
Original filing
The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).
Trial Details
NCT Number NCT06104228
Lead Sponsor Bastiaan Driehuys
Collaborators: American Heart Association
Conditions Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Enrollment 20 participants
Start Date 2024-08-12
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-24